| abstract |
A method for evaluating the efficacy, efficacy, safety and / or dosage of a therapeutic agent such as an integrin beta 7 antagonist for the treatment of gastrointestinal inflammatory disorders. Peripheral blood as an indicator (or biomarker) of efficacy, efficacy, safety, prognosis, and / or dosage of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders Intestinal homing lymphocyte levels, pharmaceutical occupancy levels in intestinal homing lymphocytes, and / or beta 7 integrin receptor levels in intestinal homing lymphocytes are provided. [Selection figure] None |